Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01207921 · ClinicalTrials.gov registry record · Phase 1
Lenalidomide Maintenance Therapy Post Autologous Transplant for Hodgkins Lymphoma
A Phase 1 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT01207921 is a Phase 1 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 28 participants.
The verdict
NCT01207921, a Phase 1 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
The purpose of this study to evaluate the feasibility of lenalidomide maintenance therapy in patients with relapsed Hodgkin lymphoma after autologous transplant
Interventions
- DRUG Lenalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2011-04-28 |
| Est. Completion | 2021-03-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01207921
The ClinicalTrials.gov registry entry for NCT01207921 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lenalidomide is the first listed.
NCT01207921 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01207921 about?
NCT01207921 is a clinical study titled "Lenalidomide Maintenance Therapy Post Autologous Transplant for Hodgkins Lymphoma". The purpose of this study to evaluate the feasibility of lenalidomide maintenance therapy in patients with relapsed Hodgkin lymphoma after autologous transplant
What is the current status of trial NCT01207921?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2011-04-28. Estimated completion is 2021-03-05.
What interventions are being tested in trial NCT01207921?
The interventions under investigation include: Lenalidomide (DRUG).
Who is sponsoring clinical trial NCT01207921?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.